Trevi Therapeutics, Inc.: Frazier Life Sciences Public Fund, L.P. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Frazier Life Sciences Public Fund, L.P. amended its Schedule 13G stake filing for Trevi Therapeutics, Inc., according to SEC accession 0001231919-26-001580. The filing updates the fund's reported beneficial ownership position in the clinical-stage biopharmaceutical company. Schedule 13G amendments are typically filed by passive investors to reflect changes in holdings above the 5% threshold. The revision matters because it signals a shift in a major institutional shareholder's exposure to Trevi. Investors will watch for further 13G/13D filings and any accompanying disclosure of the fund's current ownership percentage.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Trevi Therapeutics, Inc., Frazier Life Sciences Public Fund, L.P.